This compounded formulation is a unique blend of estriol/estradiol [80%-20%] 1.25 mg/ml - 5 mg/ml in a topical gel form, and estriol/estradiol [50%/50%] 0.5-1 mg/progesterone 50-200 mg in a troche form. The troche is a square-shaped solid dosage form designed to dissolve slowly in the mouth, delivering medication through oral mucosa absorption for targeted local or systemic effects. This combination is specifically designed to treat a variety of disease states.

For menopausal symptoms such as hot flashes, night sweats, and vaginal dryness, the estriol/estradiol component of this formulation can provide significant relief. In addition, the progesterone component is effective in reducing heavy menstrual bleeding and pain associated with endometriosis and uterine fibroids. This formulation is an effective treatment for these conditions, and can be used safely and effectively with minimal side effects.

It's important to note that the effectiveness of this formulation can vary depending on the individual's specific health needs and circumstances. Therefore, it's crucial to consult with a healthcare provider before starting any new medication regimen. If you have any questions about this formulation or how it can be used to treat these disease states, please don't hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the information and support you need.

This compounded formulation of Estriol/Estradiol [80%-20%] 1.25 mg/ml - 5 mg/ml Topical Gel and Estriol/Estradiol [50%/50%] 0.5-1 mg/Progesterone 50-200 mg Troche is designed to address a range of health conditions, including menopausal symptoms, postmenopausal osteoporosis, and as part of hormone replacement therapy. The two key components, Estriol and Estradiol, are estrogen hormones that work in tandem to alleviate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. Estriol, being a milder form of estrogen, and Estradiol, a more potent variant, provide a balanced approach to symptom management.

Progesterone, another hormone in this formulation, serves to counterbalance the effects of estrogen, thereby helping to reduce the risk of endometrial cancer. This formulation is also beneficial in the treatment of postmenopausal osteoporosis, as it aids in increasing bone density and reducing the risk of fractures. Furthermore, it is used in hormone replacement therapy to replenish the hormones that are lost during menopause.

It is crucial to be aware that this formulation may interact with other medications, including anticoagulants, anticonvulsants, and certain antibiotics. Additionally, it may increase the risk of certain side effects, such as nausea, vomiting, breast tenderness, and headaches. More serious risks include an increased likelihood of blood clots, stroke, and heart attack.

If you have any questions or concerns about this formulation or its potential interactions, it is recommended to consult with a healthcare professional for personalized advice.

This compounded formulation combines estriol/estradiol (80%-20%) 1.25 mg/ml - 5 mg/ml in a topical gel and estriol/estradiol (50%/50%) 0.5-1 mg/progesterone 50-200 mg in a troche. It is designed to address a range of conditions including menopausal symptoms, endometriosis, and uterine fibroids.

The estriol/estradiol topical gel is applied directly to the skin, typically once or twice daily. It delivers a consistent release of hormones into the bloodstream, helping to alleviate symptoms such as hot flashes, night sweats, and vaginal dryness.

The estriol/estradiol troche is a square-shaped solid dosage form designed to dissolve slowly in the mouth. It is typically taken once or twice daily and delivers medication through oral mucosa absorption for targeted local or systemic effects. This method of delivery helps to alleviate symptoms such as irregular menstrual cycles, heavy bleeding, and pelvic pain.

The progesterone troche, also a square-shaped solid dosage form, is designed to dissolve slowly in the mouth. It is typically taken once or twice daily and delivers medication through oral mucosa absorption for targeted local or systemic effects. This method of delivery helps to alleviate symptoms associated with endometriosis and uterine fibroids.

This formulation offers an effective treatment for a variety of disease states, helping to reduce symptoms and improve quality of life. For any questions or further information about this formulation, please do not hesitate to reach out.

This compounded formulation of Estriol/Estradiol [80%-20%] 1.25 mg/ml - 5 mg/ml Topical Gel and Estradiol/Estradiol [50%/50%] 0.5-1 mg/Progesterone 50-200 mg Troche is a versatile treatment option for a variety of conditions. It can be used to address hypoestrogenism, a condition characterized by low levels of estrogen in the body. It is also effective in managing postmenopausal osteoporosis, a condition that weakens bones and makes them more prone to fractures. This formulation can also be used in the treatment of breast cancer, a common type of cancer in women.

Furthermore, this formulation can be used to reduce the risk of endometrial hyperplasia in postmenopausal women who are taking conjugated estrogens. Endometrial hyperplasia is a condition that thickens the lining of the uterus and can lead to cancer. This formulation can also be used to manage symptoms of premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome that includes physical and behavioral symptoms.

Additionally, this formulation can be used to reduce the risk of endometrial cancer in women with an intact uterus who are taking conjugated estrogens. It can also be used to treat symptoms of vulvovaginal atrophy, such as vaginal dryness, itching, burning, and dyspareunia, which is painful sexual intercourse due to medical or psychological causes. If you have any questions about how this formulation can be used to treat other conditions, please consult with a healthcare professional.